ALBIO Stock Overview
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Biosynex SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.30 |
| 52 Week High | €11.00 |
| 52 Week Low | €4.53 |
| Beta | -2.37 |
| 1 Month Change | 13.73% |
| 3 Month Change | -34.57% |
| 1 Year Change | -30.35% |
| 3 Year Change | -79.62% |
| 5 Year Change | 91.34% |
| Change since IPO | -70.47% |
Recent News & Updates
Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Mar 12
Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story
Jan 20Recent updates
Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Mar 12Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story
Jan 20Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)
May 05Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital
Dec 01Biosynex (EPA:ALBIO) Could Easily Take On More Debt
Jun 23If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late
Jul 11Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock
Apr 06We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt
Dec 19Shareholder Returns
| ALBIO | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 15.2% | 0.7% | 2.2% |
| 1Y | -30.4% | 10.2% | 3.2% |
Return vs Industry: ALBIO underperformed the French Medical Equipment industry which returned 9.1% over the past year.
Return vs Market: ALBIO underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| ALBIO volatility | |
|---|---|
| ALBIO Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALBIO's share price has been volatile over the past 3 months.
Volatility Over Time: ALBIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 551 | Larry Abensur | www.biosynex.com |
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and blood pressure monitors; and oral care and medical aid products.
Biosynex SA Fundamentals Summary
| ALBIO fundamental statistics | |
|---|---|
| Market cap | €57.03m |
| Earnings (TTM) | -€34.33m |
| Revenue (TTM) | €97.00m |
0.6x
P/S Ratio-1.7x
P/E RatioIs ALBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALBIO income statement (TTM) | |
|---|---|
| Revenue | €97.00m |
| Cost of Revenue | €47.36m |
| Gross Profit | €49.64m |
| Other Expenses | €83.97m |
| Earnings | -€34.33m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.19 |
| Gross Margin | 51.18% |
| Net Profit Margin | -35.39% |
| Debt/Equity Ratio | 47.7% |
How did ALBIO perform over the long term?
See historical performance and comparison